Reproductive health effects and teratogenicity of antiepileptic drugs

Neurology

Volumn 63, Issue 10 SUPPL. 4, 2004, Pages

  Kaplan, Peter W ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; ESTROGEN; ETHINYLESTRADIOL; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LEVONORGESTREL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

AMENORRHEA; ANOVULATION; BIPOLAR DISORDER; BLEEDING; CLEFT PALATE; CLINICAL TRIAL; COGNITIVE DEFECT; CONGENITAL MALFORMATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOCRINE FUNCTION; ENZYME INDUCTION; EPILEPSY; FEMALE INFERTILITY; FETUS DEVELOPMENT; FIRST TRIMESTER PREGNANCY; HUMAN; HYPERANDROGENISM; HYPERTELORISM; LOW BIRTH WEIGHT; LOW SET EAR; MEDICAL DECISION MAKING; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MICROCEPHALY; MIGRAINE; NEURAL TUBE DEFECT; OVARY DEVELOPMENT; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PAIN; PATIENT MONITORING; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; REGISTER; REPRODUCTIVE HEALTH; REVIEW; RISK FACTOR; SIDE EFFECT; SKELETON MALFORMATION; SPINA BIFIDA; SPONTANEOUS ABORTION; TERATOGENESIS; TERATOGENICITY; TESTOSTERONE BLOOD LEVEL; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY TRACT MALFORMATION; WEIGHT GAIN;

EID: 8844276645     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.63.10_suppl_4.s13     Document Type: Review

References (134)

1. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992;327:765-771.
2. Morrell MJ, Sperling MR, Stecker M, Dichter MA. Sexual dysfunction in partial epilepsy: a deficit in physiological sexual arousal. Neurology 1994;44:243-247.
3. Guldner GT, Morrell MJ. Nocturnal penile tumescence and rigidity evaluation in men with epilepsy. Epilepsia 1996;37:1211-1214.
4. Morrell MJ, Guldner GT. Self-reported sexual function and sexual arousability in women with epilepsy. Epilepsia 1996;37:1204-1210.
5. Rosciszewska D, Buntner B, Guz I, Zawista L. Ovarian hormones, anticonvulsant drugs, and seizures during the menstrual cycle in women with epilepsy. J Neurol Neurosurg Psychiatry 1986;49:47-51.
6. Shavit G, Lerman P, Korczyn AD, et al. Phenytoin pharmacokinetics in catamenial epilepsy. Neurology 1984;34:959-961.
7. Kumar N, Behari M, Ahuja GK, Jailkhani BL. Phenytoin levels in catamenial epilepsy. Epilepsia 1988;29:155-158.
8. Karkuzhali B, Schomer DL. Weekly fluctuation and adjustment of antiepileptic drugs to treat catamenial seizures. Epilepsia 1998;39(suppl 6):179. Abstract.
9. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, Juntunen KTS, Myllylä VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388.
10. Isojärvi JIT, Pakarinen AJ, Ylipalosaari PJ, Myllylä VV. Serum hormones in male epileptic patients receiving anticonvulsant medication. Arch Neurol 1990;47:670-676.
11. Isojärvi JIT. Reproductive dysfunction in women with epilepsy. Neurology 2003;61(suppl 2):S27-34.
12. Rootwelt K, Ganes T, Johannesen SI. Effect of carbamazepine, phenytoin and phenobarbital on serum levels of thyroid hormones and thyrotropin in humans. Scand J Clin Lab Invest 1978;38:731-736.
13. Beastall GH, Cowan RA, Gray JMB, Fogelman I. Hormone binding globulins and anticonvulsant therapy. Scott Med J 1985;30:101-105.
14. Macphee GJ, Larkin JG, Butler E, Beastall GH, Brodie MJ. Circulating hormones and pituitary responsiveness in young epileptic men receiving long-term antiepileptic medication. Epilepsia 1988;29:468-475.
15. Herzog AG, Levesque L, Drislane F, Ronthal M, Schomer DL. Phenytoin-induced elevation of serum oestradiol and reproductive dysfunction in men with epilepsy. Epilepsia 1991;32:550-553.
16. Murialdo G, Galimberti CA, Magri F, et al. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 1997;20:519-526.
17. Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-451.
18. Murialdo G, Galimberti CA, Gianelli MV, et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998;21:52-58.
19. Vainionpää LK, Rättyä J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;45:444-450.
20. Rättyä J, Turkka J, Pakarinen AJ, et al. Reproductive endocrine effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001;56:31-36.
21. Victor A, Lundberg PO, Johansson EDB. Induction of sex hormone binding globulin by phenytoin. BMJ 1977;2:934-935.
22. Perucca E, Hedges A, Makki KA, et al. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401-410.
23. Isojärvi JI. Serum steroid hormones and pituitary function in female epileptic patients during carbamazepine therapy. Epilepsia 1990;31:438-445.
24. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, Juntunen KTS, Myllylä VV. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia 1995;36:676-681.
25. Dana-Haeri J, Oxley J, Richens A. Reduction of free testosterone by antiepileptic drugs. BMJ 1982;284:85-86.
26. Levesque LA, Herzog AG, Seibel MM. The effect of phenytoin and carbamazepine on serum dehydroepiandrosterone sulfate in men and women who have partial seizures with temporal lobe involvement. J Clin Endocrinol Metab .1986;63:243-245.
27. Crawford P, Chadwick DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990;30:892-896.
28. Margraf JW, Dreifuss FE. Amenorrhea following initiation of therapy with valproic acid. Neurology 1981;31(suppl):S159. Abstract.
29. Morrell MJ, Isojärvi J, Taylor AE, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res 2003;54:189-194.
30. Gidal BE, Anderson GS, Spencer NW, et al. Valproate-associated weight gain: potential relation to energy expenditure and metabolism in patients with epilepsy. J Epilepsy 1996;9:234-241.
31. O'Donovan C, Kusumakar V, Graves GR, Bird DC. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002;63:322-330.
32. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.
33. Yen SSC. Polycystic ovary syndrome. Clin Endocrinol 1980;12:177-207.
34. Balen AH, Conway GS, Kaltas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-2111.
35. Adams J, Franks S, Polson DW, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985;2:1375-1378.
36. Koivunen R, Laatikinen T, Tomas C, et al. The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand 1999;78:137-141.
37. Balen A. Pathogenesis of the polycystic ovary syndrome-the enigma unravels? Lancet 1999;354:966-969.
38. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-191.
39. Franks S. The polycystic ovary syndrome. Arch Dis Child 1997;77:89-90.
40. Hopkinson Z, Sattar N, Fleming R, Green I. The polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. BMJ 1998;317:329-332.
41. Conn J, Jacobs H, Conway G. The prevalence of polycystic ovaries in women with type II diabetes mellitus. Clin Endocrinol 2000;52:81-86.
42. Speroff L, Glass R, Kase N. Clinical gynecological endocrinology and infertility. 6th ed. Baltimore: Lippincott Williams & Wilkins, 1999:107-122, 201-246, 487-522.
43. Herzog A. Disorders of reproduction and fertility. In: Engel J, Pedley T, eds. Epilepsy: a comprehensive textbook. Philadephia: Lippincott-Raven, 1997:2013-2019.
44. Herzog A. A relationship between particular reproductive endocrine disorders and the laterality of epileptiform discharges in women with epilepsy. Neurology 1993;43:1907-1909.
45. Drislane F, Coleman E, Schomer D, et al. Altered pulsatile secretion of luteinizing hormone in women with epilepsy. Neurology 1994;44:306-309.
46. Betts T, Crawford P. Women and epilepsy. London: Martin Dunitz, 1998.
47. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341-346.
48. Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primarily generalized epilepsy. Epilepsia 1988;29:612-619.
49. Bauer J, Jarre A, Klingmuller D, Elger CE. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000;41:163-167.
50. Isojärvi JIT, Taubø E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001;111:290-296.
51. Luef G, Abraham I, Haslinger M, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002;249:835-841.
52. Isojärvi JIT, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584.
53. Rättyä J, Pakarinen AJ, Knip M, et al. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology 2001;57:440-444.
54. Morrell M, Giudice L, Flynn KL, et al. Predictors of ovarian failure in women with epilepsy. Ann Neurol 2002;52:704-711.
55. Meo R, Bilo L. Polycystic ovary syndrome and epilepsy. A review of the evidence. Drugs 2003;63:1185-1227.
56. Betts T, Button N, Yarrow H. Epilepsy and the ovary (cutting out the hysteria). Seizure 2001;10:220-228.
57. Isojärvi JIT, Pakarinen AJ, Rautio A, Pelkonene O, Myllylä VV. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur J Clin Pharmacol 1995;47:461-464.
58. Isojärvi JIT, Airaksinen KEJ, Mustonen JN, et al. Thyroid and myocardial function after replacing carbamazepine by oxcarbazepine. Epilepsia 1995;36:810-816.
59. Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependent enzyme induction by oxcarbazepine? Eur J Clin Pharmacol 1990;39:187-188.
60. Devinsky O, Vuong A, Hammer A, et al. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000;54:973-975.
61. Biton V, Mira W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-177.
62. Bauer J, Isojärvi JIT, Herzog AG, et al. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry 2002;73:121-125.
63. Weisberg E. Prescribing oral contraceptives. Drugs 1995;49:224-231.
64. Fuller S. Are all oral contraceptives created equally? Pharmacist 1997; Sept:58-74.
65. Krauss GL, Brandt J, Campbell M, Plate C, Summerfield M. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology 1996;46:1534-1539.
66. Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979;20:519-525.
67. Diamond MP, Greene JW, Thompson JM, Van Hooydonk JE, Wentz AC. Interactions of anticonvulsants and oral contraceptives in epileptic adolescents. Contraception 1985;31:623-632.
68. Back DJ, Bates M, Bowden A, et al. The interactions of phenobarbital and other anticonvulsants with oral contraceptive therapy. Contraception 1980;22:495-503.
69. Sonnen AEH. Sodium valproate and the pill. In: Akimoto H, Kazamatsun H, Seino M, and Ward AA, eds. Advances in epileptology. Proceedings of the 13th Epilepsy International Symposium. New York: Raven Press, 1982:429-432.
70. Saano V, Banield CR, Reidenberg P, et al. Effects of felbamate on the pharmacokinetics of low-dose combination oral contraceptive. Clin Pharmacol Ther 1995;58:523-531.
71. Rosenfeld WE, Doose DR, Walker SA, et al. Effects of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997;38:317-323.
72. Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J Pharm Med 1994;4:141-150.
73. Klosterskov Jensen P, Saano V, Haring P, Svenstrup B, Menge GP. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992;33:1149-1152.
74. Giuliano RA, Hiersemenzel E, Baltes G, et al. Influence of a new antiepileptic drug (Levetiracetam, ucbL059) on the pharmacokinetics and pharmacodynamics of oral contraceptives. Epilepsia 1996;37(suppl 4):90. Abstract.
75. Crawford P. Interactions, between antiepileptic drugs and hormonal contraception. CNS Drugs 2002;16:263-272.
76. Sonnen AEH. Sodium valproate and the contraceptive pill. Br J Clin Pract Symp Suppl 1983;27:31-36.
77. Crawford P, Chadwick D, Cleland P, et al. The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. Contraception 1986;33:23-29.
78. Holdich T, Whiteman P, Orme M, Back D, Ward S. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill. Epilepsia 1991;32(suppl 1):S96. Abstract.
79. Morrell MJ. The new antiepileptic drugs and women: efficacy, reproductive health, pregnancy, and the fetal outcome. Epilepsia 1996; (suppl 6):S34-44.
80. Bartoli A, Gatti G, Cipolla G, et al. A double-blind placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. Epilepsia 1997;38:702-707.
81. Eldon MA, Underwood BA, Randinitis EJ, Sedman AJ. Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol. Neurology 1998;50:1146-1148.
82. Doose DR, Wang S-S, Padmanabhan M, et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and non-obese female subjects. Epilepsia 2003;44;540-549.
83. Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999;40:783-787.
84. Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia 2002;43:697-702.
85. Sabers A, Öhman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003;61:570-571.
86. de Haan G-J, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004;63:571-573.
87. Mullers-Kuppers VM. Embryopathy during pregnancy caused by taking anticonvulsants. Acta Paedopsychiatr 1963;30:401-405.
88. Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972;2:839-843.
89. Fedrick J. Epilepsy and pregnancy: a report from the Oxford Record Linkage Study. BMJ 1973;2:442-448.
90. Kelly TE. Teratogenicity of anticonvulsant drugs I: review of the literature. Am J Med Genet 1984;19:413-434.
91. Nakane Y, Oltuma T, Takahashi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of anticonvulsants: a report of a collaborative study group in Japan. Epilepsia 1980;21:663-680.
92. Steegers-Theunissen RP, Reiner WO, Borm GF, et al. Factors influencing the risk of abnormal pregnancy outcomes in epileptic women: a multicenter prospective study. Epilepsy Res 1994;18:261-269.
93. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-158.
94. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-1138.
95. Holmes LB, Rosenberger PB, Harvey EA, Khoshbin S, Ryan L. Intelligence and physical features of children of women with epilepsy. Teratology 2000;61:196-202.
96. Olafsson E, Hallgrimsson JT, Hauser WA, et al. Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 1998;39:887-892.
97. Samrén EB, van Djujn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38:981-990.
98. Hernandez-Diaz S, Werler M, Walker A. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-1614.
99. Schupf N, Ottman R. Risk of epilepsy in offspring of affected women: association with maternal spontaneous abortion. Neurology 2001;57:1642-1649.
100. Yerby M, Cawthon M. Fetal death, malformations and infant mortality in infants of mothers with epilepsy. Epilepsia 1996;37(suppl 5):98. Abstract.
101. Pennell P. The importance of monotherapy in pregnancy. Neurology 2003;60(suppl 4):S31-38.
102. Pennell PB. Pregnancy in the woman with epilepsy: maternal and fetal outcomes. Semin Neurol 2002;22:299-308.
103. Brodie MJ, Schachter SC. Epilepsy. 2nd ed. Oxford: Health Press Limited, 2001.
104. Shorvon S, Dreifuss F, Fish F, Thomas D, eds. The treatment of epilepsy. Cambridge, UK: Blackwell Science, 1996.
105. Penovich PE, Eck KE, Economou VV. Recommendations for the care of women with epilepsy. Cleve Clin J Med 2004;71(suppl 2):S49-57.
106. Holmes LB, Wysznski DF, Lieberman E. The AED (Antiepileptic Drug) Pregnancy Registry. A 6-year experience. Arch Neurol 2004;61:673-678.
107. Sabry M, Farag T. Hand anomalies in fetal-hydantoin syndrome: from nail/phalangeal hypoplasia to unilateral acheiria. Am J Med Genet 1996;62:410-412.
108. Lu M, Sammel M, Cleveland R, et al. Digit effects produced by prenatal exposure to antiepileptic drugs. Teratology 2000;61:277-283.
109. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982;2:937.
110. Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38:981-990.
111. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-158.
112. Canger R, Battino D, Canerini M, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999;40:1231-1236.
113. Kaneko S, Otani K, Fujushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988;29:459-467.
114. Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992;42(suppl 5):75-82.
115. Holmes L, Wyazynski D, Mittendorf R. Evidence for an increased risk of birth defects in the offspring of women exposed to valproate: findings from the AED pregnancy registry. Am J Obstet Gynecol 2002;187:5137. Abstract.
116. Duncan S, Mercho S, Lopes-Cendes I, et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 2001;42:750-753.
117. Rosa F. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-677.
118. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001;153:961-968.
119. Matalon S, Schechtman S, Goldzweig G, Ornov A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002;16:9-17.
120. Montouris G. Safety of gabapentin treatment during pregnancy. Epilepsia 2002;43(suppl 7):S234. Abstract.
121. Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav 2003;4:310-317.
122. Lamotrigine Pregnancy Registry. Interim Report: 1 September 1992 through 30 September 2003. Issued January 2004. Wilmington, NC: GlaxoSmithKline, 1-3.
123. Meischenguiser R, D'Giano CH, Ferraro SM. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 2004;5:163-167.
124. Lassiter A, Mamie M-M, Cid-Rezafa, Rivière M-E. Pregnancy outcomes with oxcarbazepine (Trileptal®) therapy: a review of Novartis safety database. 6th European Congress on Epileptology, Vienna, Austria, May 30-June 3, 2004.
125. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996;37:1242-1244.
126. EURAP. An International Antiepileptic Drugs and Pregnancy Registry. Interim Report. May 2004. Available at http://www.eurap-germany.de. Accessed July 28, 2004.
127. Morrow JI, Craig JJ, Russell AJC, et al. Which antiepileptic drugs are safest in pregnancy? Epilepsia 2003;44(suppl 8):60. Abstract.
128. Long L. Levetiracetam monotherapy during pregnancy: a case series. Epilepsy Behav 2003;4:447-448.
129. Kimura S. Zonisamide: its placental transport, biological half-life in the newborn, and transport to mother's milk-a study of a case of an infant born of a mother who had been treated with zonisamide alone during pregnancy [in Japanese]. No To Hattatsu 1998;30:350-351.
130. Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001;70:15-21.
131. Adab N, Tudor-Smith C, Vinten J, Winterbottom J. A systematic review of long-term developmental outcomes in children exposed to anti-epileptic drugs in utero. Epilepsia 2002;43(suppl 7):230-231.
132. Leavitt A, Yerby M, Robinson N, et al. Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology 1992;42(suppl 5):141-143.
133. Koch S, Titze K, Zimmerman R, et al. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999;40:1237-1243.
134. Meador KJ, Pennell P, Liporace J, Kalayjian L. Antiepileptic drugs in pregnancy. Neurology 2004;62(suppl 5):A311. Abstract.